Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection
Phase 2
Terminated
NCT06585150
| Condition | RSV Infection |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Gilead Sciences |
|---|
| Status | Terminated |
|---|
| Enrollment | 150 participants |
|---|
| Interventions | Obeldesivir, Obeldesivir Placebo |
|---|
| Start date | Oct 14, 2024 |
|---|
| Completion date | May 8, 2025 |
|---|
| Results posted | Jun 30, 2026 |
|---|
Summary
The goal of this clinical study was to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it was in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers wanted to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study were to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.
Time to Alleviation of Targeted Respiratory Syncytial Virus (RSV) Symptoms as Measured by Respiratory Infection Intensity and Impact Questionnaire (RiiQ) Through Day 15
Up to Day 15 · days
| Obeldesivir | 3.2 days |
|---|
| Placebo | 3.9 days |
|---|
| p-value | 0.2005 |
|---|
| Difference in median time | -0.7 |
|---|
Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 13.5 percentage of participants |
|---|
| Placebo | 16.2 percentage of participants |
|---|
Percentage of Participants Who Experienced Treatment-emergent Laboratory Abnormalities
Up to 5 days plus 30 days · percentage of participants
| Obeldesivir | 59.5 percentage of participants |
|---|
| Placebo | 57.5 percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.